Latest Articlesddd
GlaxoSmithKline and Vir Biotechnology Announces US Gov't Contracts to Purchase Sotrovimab for COVID-19 GlaxoSmithKline plc (GSK) …
Crispr Therapeutics and ViaCyte Inc to Start Trial of First Gene-Edited Cell Replacement Therapy CRISPR Therapeutics …
Regenxbio and AbbVie Inc Agreement Regenxbio (RGNX) announced the successful closure of the collaboration and license …
U.S. Government to Purchase More of Merck and Ridgeback Biotherapeutics Molnupiravir for COVID-19 Merck (MRK) and …
Reata Pharmaceuticals Business Operations and Clinical Development Updates Reata Pharmaceuticals (RETA) – a clinical-stage biopharmaceutical company …
Intellia Therapeutics to Present at ASH Intellia Therapeutics (NTLA) announced the presentation of data from its ex …
Sangamo Therapeutics Preliminary Results Evaluating Isaralgagene Civaparvovec for Fabry Disease Sangamo Therapeutics (SGMO) announced preliminary results from …
Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation Cassava Sciences (SAVA) has been …
Reata Pharmaceuticals MAA Submission for Bardoxolone Methyl Reata Pharmaceuticals (RETA) announced the submission of a Marketing …
Merck Stock Soared Great expectations for Merck (MRK) future growth and the future of novel treatments …
Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment Gilead Sciences (GILD) and Merck (MRK) …
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ Bausch + Lomb, a leading …
Agenus to Withdraw BLA for Balstilimab Agenus (AGEN) announced a strategic decision to withdraw its Biologics …
Intellia Therapeutics Granted Orphan Drug Designation for NTLA-2001 Intellia Therapeutics (NTLA) announced that the U.S. FDA has …
Reata Pharmaceuticals Announcements Reata Pharmaceuticals (RETA) announced that the abstracts highlighting clinical data for bardoxolone methyl …
Rocket Pharmaceuticals Inc Announces Successful Results at the ESGCT Gene therapy and gene editing plus other …
Oyster Point Pharma, Inc. The U.S. Food and Drug Administration (FDA) has approved the Oyster Point Pharma Inc …
Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics (NTLA) and SparingVision - a genomic medicine company developing …
Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR Regenxbio (RGNX) announced initial …
Don’t Miss Enanta Pharmaceuticals Virtual Conference Enanta Pharmaceuticals (ENTA) – a clinical stage biotechnology company dedicated …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
